A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes

摘要

BackgroundDespite their pivotal role in the assessment of influenza vaccines, limited attempts have been made to use hemagglutination inhibition (HI) titers for predicting vaccine efficacy against laboratory-confirmed influenza. We present here the second step of a two-step approach allowing performing such predictions and use it to compare a new trivalent inactivated influenza vaccine administered by the intradermal (ID) route (INTANZA^®/IDFlU^®) with the vaccine administered by the classical intramuscular (IM) route.